Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ribonucleotide reductase R2 subunit (RRM2, M2, or R2) is a critical component of the ribonucleotide reductase (RNR) enzyme complex, which catalyzes the reduction of ribonucleotides to deoxyribonucleotides—the essential precursors for DNA synthesis and repair. It is a homodimer, where each monomer harbors a dinuclear iron center that is crucial for generating and stabilizing a tyrosyl radical, which initiates the radical-based chemistry required for nucleotide reduction. Overexpression or dysregulation of RRM2 has been linked with increased tumorigenesis, cancer progression, and drug resistance. It is a therapeutic target in oncology.
Inhibition of ribonucleotide reductase activity by scavenging tyrosyl radicals, thereby blocking DNA synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleotide Reductase R2 Subunit (RRM2).